A Phase I Study of CX5461
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
At a glance
- Drugs CX 5461 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- 25 Jul 2018 Phase has been changed from I/II to phase I, hence planned number has reduced and primary endpoint has been removed for phase II. Hence trial focus TU has been removed.
- 25 Jul 2018 Planned number of patients changed from 98 to 60.
- 14 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.